following CRt, pathologic complete response (pCR) rates range from 8% to 27%, 4, 5 and many additional patients will have a significant reduction in tumor size. Because the morbidity from tme is high, [6] [7] [8] [9] less invasive treatment strategies following CRt are becoming more popular. these strategies include watchful waiting for patients with apparent complete clinical response, [10] [11] [12] [13] and transanal local excision or transanal endoscopic microsurgery for patients with residual, small lesions. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Poor defecatory function following tme is common, 26, 27 whereas local excision of rectal tumors results in low fecal incontinence and defecatory dysfunction rates and improved patient quality of life compared with tme. 28 one of the disadvantages of watchful waiting or local excision, however, is a lack of definitive pathologic lymph node (ln) staging. Potential residual positive lns in the mesorectum can lead to local recurrence or distant spread.
Certain pretreatment clinicopathologic factors have been shown to be associated with pCR after CRt. these factors include circumferential tumor extent, Cea level, distance from the anal verge, macroscopic ulceration, interval between CRt treatment completion and surgical resection, clinical t and n classification, and histologic grade. [29] [30] [31] [32] [33] however, few studies have examined preoperative clinicopathologic factors predictive of ln positivity after CRt. 34 We used the national Cancer Database (nCDB) to identify clinically available factors that are associated with ln positivity following CRt for locally advanced rectal cancer. using this information, we created a nomogram to help quantify an individual patient's risk of ln positivity based on these factors.
MATERIALS AND METHODS
the nCDB is a collaborative effort between the american Cancer society and the american College of surgeons Commission on Cancer. established in 1989, this database captures clinicopathologic, primary treatment, and outcome information for approximately 70% of new cancer diagnoses in the united states. We used the nCDB registry to identify patients aged 18 to 90 diagnosed with clinical stage t3/t4, n0, m0 or tany, n1-2, m0 adenocarcinoma of the rectum who underwent CRt before tme with either low anterior resection or abdominoperineal resection from 2010 to 2012. Data from 2009 and earlier were not used because certain clinicopathologic information, particularly lymphovascular invasion (lVi), was not available. Patients who underwent local excision following neoadjuvant therapy, who had incomplete clinical and pathologic staging information, or who received less than 4500 Gy of neoadjuvant radiation were excluded.
We first identified the clinicopathologic variables available in the data set that may be available to a provider before surgical intervention and that may be related to pathologic nodal positivity. the variables included were patient age, race, sex, Charlson comorbidity, histology, tumor grade, Cea level, lVi, t stage, and clinical ln status. Age was analyzed as a continuous variable. Race was categorized as white, black, Hispanic, and other. The nCDB provides a precalculated Deyo-Charlson score, categorized as 0, 1, or 2+. Tumor grade was categorized as well differentiated, moderately differentiated, poorly/ undifferentiated, and unknown. We defined histology subtypes of nonmucinous, nonsignet ring (International Classification of Diseases for Oncology, 3rd Edition surveillance, epidemiology, and end Results (seeR) site/histology codes 8140, 8210, 8211, 8220, 8221, 8260, 8261, 8262, 8263) and mucinous/signet-ring (International Classification of Diseases for Oncology, 3rd Edition seeR site/histology codes 8480, 8481, 8490). Cea level was classified as elevated, normal, or unknown. LVI was categorized as present or absent/unknown. T stage was categorized as t1, t2, t3, or t4. the primary outcome was pathologic ln status, which was defined as negative or positive, and was ascertained directly from the pathologic staging variables available in the data set.
Statistical Analysis
Patients were randomly assigned to either the model development (75%, n = 6738) or the validation (25%, or n = 2246) cohort. Descriptive statistics were performed. We first used bivariate logistic regression to assess the association between ln positivity and each predictor variable. significant predictors were then included in the multivariate logistic regression model. to further select variables from the multivariate model, we performed bootstrapping resampling with 500 repetitions. the final predictive model was determined by including predictors that were statistically significant in at least 50% of the bootstrapped replicates. the results of the final prediction model were then represented as a nomogram. We evaluated the discrimination and calibration abilities of the prognostic model using receiver operating characteristic techniques and the hosmer-lemeshow test. in addition, we plotted calibration curves showing the actual versus predicted rate of ln metastasis.
for most prediction models with a binary outcome, 50% is used as the cutoff for positive or negative outcome. Clinically, this predicted probability is too high. Clinicians cannot make decisions regarding treatment strategy based on an even likelihood of ln positivity. as a result, in this study, we found it essential to create a model with high sensitivity; that is, we wanted to accurately capture those with a high likelihood of positive nodes. We calculated the true positive rates (sensitivity) of our final model at different predicted probability thresholds. all evaluation tests were performed in the development and the validation cohort. a p value of 0.05 (2-tailed) was considered statistically significant in all analyses. statistical analyses were performed using stata 14 (stataCorp, College station, tX). this study was approved by the institutional Review Board at the university of Pennsylvania.
RESULTS
We identified 8984 patients with clinical t3/t4, n0, m0 or tany, n1-2, m0 rectal adenocarcinoma who underwent CRt followed by tme from 2010 to 2012. the clinicopathologic characteristics of both the development and validation cohorts are presented in table 1. as expected, there was no significant difference in any of these characteristics between the 2 cohorts. in our study, patients had a mean age of 59 years, 62% were men, and over 80% were white. lVi was present in 13%, and an elevated Cea was noted in over 30% of patients. tumors were moderately differentiated in 70% and had mucinous, signet-ring histology in 7%. over 50% of patients had clinically positive lns before CRt.
overall, 35.6% of the cohort had pathologically positive nodes following tme. even pt0-2 tumors had a significant rate of ln positivity; 15% of pt0, 17% of pt1, and 25% of pt2 tumors had positive pathologic nodes. for patients with pt3/t4 tumors, the rate of positive lns was 46%.
Results of the bivariate and multivariate analysis of the association of clinicopathologic characteristics and ln positivity, determined after the bootstrapping method described above, are shown in table 2. Younger age, lower Charlson comorbidity, mucinous histology, poorly/undifferentiated tumors, the presence of lVi, elevated Cea, and clinical ln positivity were predictive of pathologic ln positivity following neoadjuvant CRt (p < 0.05).
it is noteworthy that clinical t stage was not included in the final model because, based on our sample selection criteria, the collinearity of t stage with clinical n stage led to instability in the estimates of the other model coefficients. specifically, we evaluated patients who had received neoadjuvant CRt for a standard indication -clinical t3/ t4, n0, m0, or tany, n1-2, m0. t stage is thus inherently associated with clinical n stage, because all the t1/2 patients had clinically positive nodes. Because clinical node positivity is associated with pathologic node positivity, this made t1 and t2 appear to be associated with patho- logic nodal positivity, compared with t3/t4. to avoid this spurious result, we opted to exclude t stage from the nomogram. a nomogram predicting the risk of ln positivity was constructed based on these 7 variables ( fig. 1) . to use the nomogram, a vertical line is drawn from each variable to the associated score below. then, the total score is calculated as the arithmetic sum. finally, a vertical line is drawn from the total score to the probability row above to determine the probability of lymph node positivity. for example, a patient who is 55 years old (points = 3.2), with a Charlson score of 1 (points = 2.5), with clinically negative nodes (points = 0), unknown lVi (points = 0), elevated Cea (points = 0.5), and a poorly differentiated (points = 2.8), nonmucinous tumor (points = 0) would have a point total of 8.8 and a predicted ln positivity rate of approximately 30% to 35%. the equation produced by our model is included for review in appendix a. this equation can be used to calculate the exact probability of ln positivity based on the variables in the model. in the development cohort, the predictive accuracy of the basic model was 70.9%, with a c index of 0.71. there was minimal deviation between the predicted and observed outcomes ( fig. 2a) . in the validation cohort, the accuracy was 71.6%. the predicted and observed outcomes were again very similar and are shown in fig. 2B . hosmer-lemeshow tests showed no lack of fit. When evaluating the robustness of clinical prediction models, results are often based on a 50% threshold. that is, if the model predicts over 50% probability of the outcome, this is considered positive. in clinical practice, a 50% threshold is considered too high to inform surgical decision making in rectal cancer. for example, if a patient has less than 50% predicted probability of ln positivity, this would not necessarily prompt a practitioner to recommend a less radical surgery. similarly, if the predicted probability of ln positivity was 25%, this might lead a provider to recommend tme. to address this, we examined the predictive accuracy of the model at different predictive thresholds. these are shown in table 3. for example, if a cutoff of 0.5 is used, the associated true positive rate is 34%; in other words, only approximately 34% of patients who actually have positive nodes would be identified. if, however, a threshold of 0.3 predicted risk of positive nodes is used, almost 80% of patients who have positive nodes will be correctly identified. By using a threshold of 0.2, 90% will be correctly identified.
DISCUSSION
We used the nCDB, a large national database, to create a nomogram using clinically available factors to help predict ln positivity following CRt for locally advanced rectal cancer. Our results are similar to those of Jwa et al, 34 who showed in a single-institution study that pretreatment ypt stage, younger age, poor pre-CRt tumor differentiation, clinical ln stage, lVi, and perineural invasion were predictive of positive lns after CRt for locally advanced rectal cancer. in their study, however, the authors included several factors only available from a pathologic specimen, such as ypt stage and perineural invasion. our study, in addition to being a much larger, national-level analysis, included only factors that are available to the clinician before surgical decision making.
it is not surprising that adverse histopathologic features such as lVi, poorly/undifferentiated histology, and mucinous features all significantly increase the risk of positive mesorectal nodes. however, it is interesting that young patients and patients with lower Charlson scores are more likely to have positive nodes. the association of young age and positive lns may signify later stage at diagnosis in young patients, who often are diagnosed after symptoms prompt a colonoscopy. it may also imply a more aggressive biological behavior. an increased rate of rectal cancer in patients 50 and younger has prompted recent examination of the clinical and biological behavior of rectal cancer in this age group, as well as scrutiny of current screening parameters. 35 older patients may be diagnosed more frequently at an earlier stage, during screening, before symptoms develop. meyer et al, 35 in a recent review of the seeR database, also found younger age to be associated with increased rates of ln positivity, which was also attributed to more aggressive tumor biology in younger patients. it is likely that the association between lower Charlson score and ln positivity is due to similar factors. in this cohort, the patients with Charlson scores of 0 and 1 are significantly younger than those with Charlson scores of 2+. The older patients with a higher comorbidity burden may use the health care system more frequently, receive screening colonoscopies more often, and be diagnosed at earlier stages than their counterparts with fewer comorbidities. these data suggest that younger, healthier patients, especially those with poor histopathologic features, may be the very patients who would benefit most from tme. these findings should impact selection criteria for "watchful waiting" nonoperative surveillance programs after CRt.
accurate ln restaging following CRt is critical when local excision or watchful waiting surveillance strategies are being considered. in 2 small, single-institution studies, including 118 patients total, the accuracy of ln restaging with Ct, Pet/Ct, mRi, or endoscopic ultrasound is only 62% to 75% depending on the imaging technique used. 36, 37 a review published in 2013 examining the reliability of imaging for restaging following CRt for rectal cancer concluded that prediction of ln positivity was still poor, with no consensus regarding standard definitions of ln positivity. 38 We believe that our nomogram can serve as an important complement to imaging and clinical examination in assessing the likelihood of nodal positivity following CRt. Choosing a less invasive treatment approach for rectal cancer is a difficult and complex decision for both the physician and patient that is often made with a dearth of evidence. this nomogram is a useful additional tool for both physicians and patients that can uniquely and distinctly supplement imaging and biopsy of the primary with an array of clinical data points. it is straightforward to implement, it is easy to understand, and its results can be used to help inform the risk-benefit discussion.
We do recognize that although relying on lower predictive thresholds increases the nomogram sensitivity, it reduces the specificity. that is, if lower predictive thresholds are used as a cutoff for ln positivity, more patients who have pathologically negative nodes will be captured in the predicted positive group. We believe this is an acceptable tradeoff, however. Clinically, it is within the current standard of care to perform proctectomy with the understanding that all lns may be negative on final pathology. it is far less acceptable to perform local excision alone in a patient who ultimately has positive mesorectal nodes.
our study has several limitations. first, the data are retrospective and may have coding errors, although the nCDB is a validated and widely used cancer database. second, we only have data for patients who underwent radical excision following CRt; we have no data for those patients who underwent local excision or watchful waiting. thus, this sample may be biased toward patients with higher-risk tumors whose surgeons selected radical resection over less-invasive strategies. unfortunately, this is an unavoidable bias given that pathologic nodal information is only available following proctectomy, although in reality, during the study years, the standard of care in this country was to offer radical resection following CRt for all patients with locally advanced rectal cancer. although there is more evidence now to support watchful waiting of pCR or local excision for good responders, these strategies were not common practice before 2012. third, the data set does not specify when during the course of treatment these variables were derived. all these patients had definitive proctectomy, and some of the histopathology is likely from the final pathologic specimen rather than the preoperative biopsy specimen. however, the variables we evaluated are all potentially available either pre-CRt or preoperatively. even lVi can be diagnosed on a biopsy specimen, although it is not always possible to do so. When lVi is present on a biopsy specimen, it is reported. if lVi is not seen on a biopsy, it could be either absent or missed because of a sampling error from the larger tumor. hence, we believe our classification of this variable as present or an additional limitation is that we cannot determine the imaging modality, for example, mRi vs endorectal ultrasound, used to determine the clinical nodal stage. each imaging modality has different sensitivities for identifying clinically positive nodes; thus, the value of clinically positive lns as a predictor of pathologically positive lns may vary based on the imaging modality used. however, during the time period of this study, both mRi and endorectal ultrasound were used in clinical practice, and this cohort likely represents a mixture of the two. if anything, including modalities with lower sensitivity for ln positivity should bias the results toward the null, that is, reduce the association between clinical and pathologic ln positivity. as clinical imaging modalities have improved and the sensitivity for diagnosing clinically positive nodes has increased, it is likely that the association noted here has only strengthened. a final limitation is that certain other variables that may impact the risk of nodal positivity and the decisions regarding post-CRt surgery are not available in the nCDB data set. for example, we have no information on the appearance of the bowel wall post-CRt, which may be used by some surgeons to help inform surgical decisions. We also do not have information regarding tumor characteristics such as tumor budding, invasive front differentiation, sm stage, or various genetic mutations such as microsatellite instability or p53, that likely are associated with nodal positivity.
the strengths of our study include the large and representative sample drawn from a national database and the practical clinical utility of the nomogram. our nomogram is designed to predict presurgery likelihood of ln positivity, and all variables included would be available before surgery. the variables included are also simple to determine and should require no additional tumor/genetic testing, making implementation straightforward.
CONCLUSION
We have used a national cohort of almost 9000 patients to create a nomogram based on preoperatively available clinicopathologic features to predict ln positivity following CRt for locally advanced rectal cancer. in this patient population, less-invasive, rectal-sparing approaches following CRt, as well as alternatives to current chemoradiation paradigms, are becoming increasingly popular despite lack of definitive posttreatment nodal staging. this model may serve as a valuable tool to augment the clinically available evidence, including imaging, possibly biopsy, and other tumor information, to help inform the discussion between surgeons and their patients regarding choice of treatment. 
